The classical clinical signs of deep vein thrombosis (DVT) are unspecific and may be found in several other conditions besides DVT. Therefore, patients suspicious of DVT are subjected to elaborate invasive or noninvasive evidencebased procedures that actually confirm DVT in only 20% to 30% of patients in this setting. However, simple laboratory tests and noninvasive strategies to exclude and diagnose DVT are becoming available in the clinical emergency setting of outpatients. In the presented literature, a sound basis is provided for quantifying clinical judgment for the diagnosis of acute proximal DVT. The number of positive clinical findings at time of first suspicion of DVT appears to correlate directly with the probability of acute proximal DVT. The modified clinical model of Landefeld and Wells for DVT allows reasonable accurate classification of patients into low, moderate, and high probability for suffering DVT. The rapid automated enzyme-linked immunoabsorbant assay (ELISA) VIDAS Ddimer presently available can be rapidly performed in daily practive and emergency situations and is accurate to a high degree, especially in ruling out ongoing venous thromboembolic processes. The sequential use of the rapid ELISA VIDAS D-dimer test and compression ultrasonography in a welldesigned clinical setting using a simple clinical model predicts a significant improvement due to a high sensitivity near 100% for the exclusion and diagnosis of DVT in the majority of outpatients with suspect DVT. A prospective decision analysis management study is proposed to exclude and diagnose DVT based on the rapid ELISA VIDAS D-dimer test and compression ultrasonography within the context of a ready-to-use simple clinical model. The proposed simple model of a rational diagnosis of deep vein thrombosis (RADIA DVT) has to be tested in a large multicenter study of more than 1,000 outpatients with suspected DVT. This model would be less expensive, easy to perform, and likely yield a significant simplification and improvement of highly accurate evidence-based exclusion or diagnosis of DVT on the basis of which clear-cut indications of anticoagulation could be appropriately initiated or safely withheld.
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The annual incidence of a first episode of deep venous thrombosis (DVT) has been estimated at 2 to 4 per 1,000 inhabitants per year (1) . This suggests that about 300,000 to 400,000 patients per 100 million inhabitants are to be investigated each year for suspected DVT. The natural history of DVT usually starts in the calf.
The therapeutic implications of calf vein thrombosis (CVT) (2-4) still remain equivocal, but symtomatic CVT deserves the merit of anticoagulant treatment (5) . When CVT produces symptoms, 80% of them progress to the popliteal veins. In patients with isolated CVT on venograms, about 20% of them subsequently extend into the proximal veins usually within a week after presentation. Nonextending CVT rarely causes pulmonary embolism, whereas popliteal, femoral, and ileofemoral DVT often does. As clinical assessment alone appears to be unreliable, objective testing for DVT is crucial. Accurate probability estimates are important because proximal DVT is life threatening and can be treated effectively (6, 7) . It is desirable to initiate appropriate diagnostic testing and to avoid the costs and complications of unnecessary testing and treatment. However, the decision to exclude or diagnose leg vein thrombosis in outpatients with suspected DVT is not yet defined.
This article discusses venography and reviews the noninvasive strategies to exclude and diagnose DVT. Compression ultrasonography has many advantages over venography CUS and thus became the diagnostic test of choice in most general and teaching hospitals. It is noninvasive, easy to repeat, free of complications, and relatively inexpensive. In addition, such abnormalities as Baker cyst or aneurysm, hematoma, etc., which could mimic DVT, are easily recognized by CUS. Compression ultrasonography has two main potential disadvantages. First, clinicians should be aware that isolated thrombi in the iliac vein and superficial femoral vein within the adductor canal are difficult to detect and can easily be overlooked in symptomatic patients with suspect DVT (10) . Second, the majority of CVTs are overlooked by CUS. The sensitivity of CUS for CVT is The most accurate and single criterion for the presence of DVT is noncompressibility of the vein under a gently probing pressure (compression ultrasonography [CUS] ). It is safe to limit CUS examination of the proximal veins to the common femoral and popliteal veins.
DVT, deep vein thrombosis; CVT, calf vein thrombosis. (14) , because of the small size and the anatomical variation of these vessels. However, CVT does not necessarily need anticoagulant therapy. The absolute incidence of CVT in outpatients with suspect DVT is about 4% to 10% ( Table 2 ) and about 20% to 25% of CVT patients will develop ascending thrombosis within a few days or weeks and that will be detected by repeated CUS examination. Therefore, it can be calculated that after a first negative CUS, the incidence of developing proximal DVT from ascending CVT will be about 1% to 3%. A negative first CUS overlooks asymptomatic and symptomatic CVT, which may progress to the proximal veins of the symptomatic leg within a few days to 1 week. This implicates that in all symptomatic patients suspicious of DVT, but with a negative first CUS, a second CUS has to be performed within 1 week to detect the progression of a CVT to proximal DVT (19) (20) (21) (22) . The majority of outpatients suspicious of DVT do not have DVT as documented by an initial normal noninvasive CUS test and therefore undergo repeated testing within 1 week accord-ing to different consensus or strategy recommendations (19) (20) (21) (22) . The central question in those patients with suspected DVT and a first negative CUS is whether a second CUS can be restricted to those with persistent symptoms (strategy A, Table 3 ) or should routinely be performed in all of them (strategy B, Table 4 ).
Strategy A
In two large series by Cronan et al. (20) and Vaccaro et al. (21) , of 537 and 1,355, respectively, outpatients with symptomatic DVT, 22% and 28%, respectively, had a positive first CUS, 78% and 72%, respectively, had a negative first CUS for DVT at day 1, and an alternative diagnosis was detected in 8% and in 10.9%, respectively (Table 3) . A second CUS at 48 to 74 hours was performed in a minor proportion of patients with a negative first CUS because of persistent symptoms. In the study of Cronan et al. (20) , a second CUS was performed in 24 patients and venogram in 2 of 378 for a total of 26 (6.9%) patients with a negative first CUS. A positive DVT was found in 4 ( 1.1 %) patients and no venous thromboembolism (VTE) was recorded during follow-up. In the study of Vaccaro et al. (21) a second CUS was performed in 86 (7.7%) patients and was found to be positive in 9 (0.9%) of 1,022 patients with a first negative CUS. In addition, 10 venograms and 14 CUSs were performed in 46 patients with an inconclusive first CUS and found to be positive for DVT in 10 (1%). During subsequent follow-up of the 1,022 patients for more than 8 months, 3 (0.5%) VTE were recorded and two (0.2%) patients died of pulmonary embolism (PE) more than 3 months after the first negative CUS. The strategy to restrict a second CUS within 1 week after a negative first CUS to a small group of those with persistent symptoms is safe and effective with a posttest thrombosis risk ~0.5%.
Strategy B
In two other large series of outpatients with a first suspicion of DVT, three-fourths of them with a negative CUS at day 1 underwent repeated CUS at day 7 (Table 4 ) (22, 23) . In the study of (23) . The strategy of a second CUS in all patients with a negative first CUS is safe but you have to repeat 100 CUSs to find 1 CUS positive for DVT, which is not as cost-effective as compared to the repeated CUS strategy of a second CUS in a minor group of patients if symptoms persist at 40 to 72 hours (Table 3) (20, 21) . Therefore it has become daily practice by experienced clinicians that a significant number of outpatients with a normal initial CUS and minor or atypical symptoms (low/moderate pretest clinical probability [PCP]) do not undergo repeated CUS tests within 1 week, except when signs and symptoms persist or increase (Table 3 ) (10).
EXCLUSION AND DIAGNOSIS OF DVT BY CUS

AND OF A SIMPLE CLINICAL MODEL
Working hypothesis
When outpatients present with suspect DVT in the evening, during the night, or on the weekend, there is uncertainty on the most appropriate diagnosis solution and strategy (1) . When a combination of clinical signs and symptoms (clinical model) with a simple laboratory test (rapid enzyme-linked immunoabsorbent assay [ELISA] D-dimer test) and/or a widely used noninvasive imaging technique (CUS) can reduce the posttest probability of having leg vein thrombosis to <1 %; this will obviate the need of further noninvasive or invasive methods to exclude or diagnose DVT. This article discusses the contribution of a simple clinical model in assessing the pretest and posttest probability of having leg vein thrombosis, the place and effectiveness of a rapid ELISA D-dimer test to exclude CVT and DVT and the most cost-effective way to diagnose and exclude DVT by the sequential use of a rapid ELISA D-dimer test, CUS testing, and repeated CUS only if symptoms persist. Clinical model for predicting pretest probability for proximal DVT Unilateral increase of calf circumference, pain, tenderness and leg edema may be indicative for DVT or for conditions that mimic DVT. Alexander et al. (24) demonstrated the inaccuracy of signs and symptoms in 166 patients with suspect venous thromboembolism (DVT, n = 113 and PE, n = 53) by comparative analysis of the signs and symptoms for DVT in suspected patients with phlebographic proven presence and absence of DVT. In this study only 58% of the thrombi were found in the proximal ileofemoral deep veins. However, 44% of the thrombi were found in the calf, popliteal, and/or superficial femoral veins explaining the paucity of the presenting signs and symptoms of leg vein thrombosis.
Richards et al. (25) analyzed the physical signs and symptoms in a prospective study of 85 patients (25) with suspect DVT in whom DVT was excluded or diagnosed by bilateral phlebography. The frequency of true-positive (26) and false-positive signs and symptoms of DVT is listed in Table 5 .
In this study, 60 of 150 evaluated phlebograms were found to contain deep vein thrombi, which were confined to the thigh in 25 patients, popliteal region in 12, and the calf in 23. All clinical signs, whether considered individually or in combination, were associated with an unacceptable frequency of false-positive and false-negative results. Each of the clinical signs was present in 27% to 63% of symptomatic patients with venographically documented DVT, but only in 9% to 13% in symptomatic patients with no DVT on venograms. Each of the positive physical signs carries a relative risk of 2.1 to 3.2 of having DVT (Table 5 ) (25) . The reason for the inaccuracy of clinical judgment in diagnosing DVT is that none of the signs and symptoms is unique and many other conditions can mimic DVT such as superficial thrombophlebitis, Bakers cyst, trauma, muscle tear, postthrombotic syndrome, external venous compression due to malignancy, edema due to congestive heart failure, lymphangitis, lymphedema, and cellulitis (8) . The frequency of such alternative diagnoses mimicking DVT is 9% to 12% (20, 21) .
Strategies for using accurate testing to exclude or diganose acute proximal DVT always starts with and must be based on clinical suspicion. Landefeld (Table 6 ).
Five clincial findings could be identified to be independently related to positive venograms as showed by linear discriminant analysis: cancer, immobility, swelling above the knee, swelling below the knee, and fever ( Table 7) . Increase of calf swelling in the affected lower leg was a sensitive indicator of acute proximal DVT. The striking differences in calf circumferences between the affected and the normal legs in patients with DVT (p = .0001, Table 7 ) strongly suggest that such measurements are helpful and should be included in the workup in patients with suspect venous thromboembolism.
As shown in Fig. 1 , the number of clinical findings present was correlated directly with the probability of acute proximal DVT. In patients with none, one, two, and three or more of these clinical findings, venographi- cally proven DVT was present in 8%, 14%, 35%, and 55%, respectively. Subsequently, Landefeld et al. (26) tested the predictive accuracy of the number of clinical findings in an independent testing group of 119 patients with suspect DVT. In this testing group, the probability of proximal DVT was also predicted by the number of clinical symptoms present (Fig. 1 ). In the groups of patients with none, one, and two or more of these clinical findings, phlebographically proven DVT was present in 5%, 15%, and 42%. Landefeld et al. (26) Fig. 1 ). The presence of an alternative diagnosis as likely or greater than that of DVT was scored as minus 2. When the PCP model is used by inexperienced observers such as physicians in training for internal medicine or surgery, the assumption of no alternative diagnosis is likely to ensure the highest level of safety in predicting the clinical probability for proximal DVT (28) . Therefore, we propose not to use &dquo;alternative diagnosis minus 2 scores&dquo; in the modified clinical model of predicting the probability of proximal DVT ( (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . As the incidence of DVT in the low-PCP group was 3.8%, further testing by CUS or a D-dimer test for the exclusion and diagnosis of DVT is still warranted. The sensitivity and negative predictive value of CUS for the exclusion of angiographically proven DVT decreases from 99, 95% to 76% with a post-CUS probability of DVT of 0.3%, 3.6%, and 31% in the low-, moderate-, and high-PCP groups, respectively (Table 9 ) (27) (28) (29) . This implicates that the combination of a low-PCP and negative CUS excluded DVT with a negative predictive value of 99.7% without the need for serial CUS testing (Table 9 ) (19, 27) . This comprises about half of the patients suspicious of DVT in the studies of Wells et al. However, symptomatic patients with moderate PCP and a negative initial CUS still have a posttest clinical probability of DVT between 1 % and 10% and warrants serial CUS testing or phlebography (Table 9 ). Patients with a high PCP and a negative initial CUS test have a high posttest clinical probability (31 %) of having DVT and are candidates for venography or repeated CUS at days 1, 2, and 7.
The main advantage of the clinical model is to select a minor group (3.4%) of high-risk patients with a negative CUS but a posttest probability of having DVT of about 30%, who are candidates for the criterion backup strategy of admission, venography, or repeated CUS (Fig. 2 ).
THE PLACE OF D-DIMER TESTING FOR THE
EXCLUSION OF DVT D-dimer strategy after a first negative CUS A possibility to simplify and improve the workup is a stepwise decision strategy by the combination of CUS in the first step and a qualitative D-dimer test in the second step of the decision rule. Bernardi et al. (29) recently demonstrated that the combination of a first negative CUS plus a negative qualitative D-dimer (Instant DD) test reduces the incidence of VTE after a first negative CUS from 1% to 0.3%. On the basis of this result they concluded that the combination of a first negative CUS and a negative qualitative D-dimer test will exclude posttest DVT without the need of a second CUS on the basis of which anticoagulant therapy can safely be withheld (Table 10 ). The combination of a negative CUS and Ddimer test has a very high-negative predictive value (>99.5%) because only one DVT was observed during a 3-month follow-up of 598 untreated patients with an initial normal CUS and a negative D-dimer test. A second CUS at day 7 was found positive in 5 of 88 outpatients (Table 8) . A gold standard strategy to exclude DVT by a negative rapid ELISA D-dimer test in the first step irrespective of PCP and to exclude and diagnose proximal DVT in patients with a positive rapid ELISA D-dimer test by the combined use of CUS and PCP. The safety and efficacy of this criterion exclusion and backup strategy has to be tested in a prospective multicenter management study of more than 1,000 outpatients with suspected DVT. DVT, deep vein thrombosis; ELISA, enzyme-linked immunosorbent assay; PCP, pretest clinical probability; CUS, compression ultrasonography.
Addendum to the Study Design in Figure 2 with the combination of a negative first CUS and a positive D-dimer test indicating the need to repeat CUS testing. The strategy of D-dimer testing after a first negative CUS is equally effective as compared to strategy A of a second CUS if symptoms persist after a first negative CUS (Table 3 ) (20, 21) , but is more costly because you have to perform 100 D-dimer tests after a first negative CUS to reduce the post-CUS incidence of DVT from 1 % to <0.5% (Table 10 ) (29) .
Golden exclusion of DVT by a rapid ELISA D-dimer test without the need of CUS A simplified and most cost-effective strategy of excluding DVT by an ELISA D-dimer test alone as a first step to exclude DVT without the need of CUS testing is very promising (Tables 11, 12;  Fig. 2) (30,31) . The classical ELISA D-dimer test was demonstrated to have a near 100% sensitivity and negative predictive value for the exclusion of phlebographically proven DVT irrespective of PCP (Table 11 ) (30, 31) . The negative predictive value of the qualitative Simplired (Agen, Queensland, Australia) latex D-dimer tests is not sensitive enough for the exclusion of phlebographically proven DVT (Table 11 ) (32) . In contrast, the quantitative rapid ELISA VIDAS D-dimer test (BioM6rieux Marcy 1'Etoile, France) has a sensitivity and negative predictive value of 100% in two subsequent studies and one pilot study of phlebographically documented DVT. The interesting finding is that a negative rapid ELISA D-dimer test will exclude proximal and distal DVT (Table 11 ) (30, 31) . This has two important implications. First, a negative rapid ELISA D-dimer test will always be followed by a negative CUS. Second, the posttest probability of developing DVT after a negative rapid ELISA test is far below 1% and thus excludes all DVT without the need of CUS on the basis (19, 27, 28) of which anticoagulant therapy can safely be withheld (Fig. 2 ). The reverse is not the case, that is, the negative predictive value of CUS alone for all DVT is 90%. Therefore, it can be predicted that a negative rapid ELISA D-dimer test will safety and effectively exclude DVT in patients with a first suspicion of DVT irrespective of PCP (Fig. 2 ). To validate this strategy to improve and simplify the diagnostic tract, we recently proposed (28) to evaluate standard diagnosis of DVT by the combined use of CUS and a rapid ELISA D-dimer test simultaneously in comparison to the stepwise strategy to exclude DVT by a negative rapid ELISA D-dimer test in the first step and the combination of a negative CUS and a positive ELISA D-dimer test is followed by repeated CUS testing in the low-and moderate-PCP groups if symptoms persist (20, 21) . As compared to standard diagnosis of DVT using CUS alone, the stepwise golden exclusion of DVT by a normal rapid ELISA D-dimer test result followed by exclusion and diagnosis of DVT by CUS within the context of a ready-to-use, simple clinical model (Table 8 , Fig. 2 ) will be the most cost effective by the reduction of CUS examinations by 25% to 50% leading to decreasing costs and gaining time for the patient and the doctor.
The proposed strategy of golden exclusion of DVT by a negative rapid ELISA VIDAS D-dimer test result alone in the first step without the need of CUS testing (Fig. 2) (30,31) fulfills the three conditions necessary for such a strategy: (a) 100% sensitivity to venous thromboembolism (Table 11 ), (b) individual use, and (c) availability in (33) . Of the 474 patients with suspect DVT, the 127 (26.7%) patients with a negative rapid ELISA D-dimer test result had a negative CUS and a posttest incidence of VTE at 3 months of 0%, whereas the 236 (49.8%) patients with a negative CUS and a positive rapid ELISA D-dimer test had a posttest incidence of VTE at 3 months of 3% (n = 7, Table 12 ) (33) . As the group of patients with a negative first CUS but a positive rapid ELISA D-dimer test belong to the lowand moderate-PCP groups, repeated CUS testing is only indicated if symptoms persist (Table 12 , Fig. 2 ) (33). The 109 (23%) patients with a positive CUS all had a positive rapid ELISA D-dimer test.
CONCLUSION
The practice of withholding CUS testing and anticoagulant therapy on the basis of a negative rapid ELISA VIDAS D-dimer test result as the new consensus strategy of excluding DVT requires a confirmative validiation by a cost-effectiveness analysis in a prospective multicenter management study in outpatients with a first suspicion of DVT (Fig. 2) . To get the precise answer on the addressed questions, it is important to characterize the studied groups of randomized patients with suspect DVT precisely and to know how many patients with low-, moderate-, and high-PCP will be selected for each of the study arms of the proposed project. Therefore, we also recommend performing a prospective evaluation of the claimed additional value of a simple clinical model by implicating the PCP for the decision analysis to exclude and diagnose DVT.
